Michelle Slade

Rational Design of Highly Selective Spleen Tyrosine Kinase Inhibitors

Matthew C. Lucas, David Goldstein, Johannes C. Hermann et al. · Journal of Medicinal Chemistry · 2012 · 49 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

Cheng Liao, Jonathan Hsu, Yong Kim et al. · Arthritis Research & Therapy · 2013 · 46 citations · Full text

Medicine, Immunology, Pharmacology +17

Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation via Distinct Structural Degrons

Mary E. Matyskiela, J. Zhu, Joshua M. Baughman et al. · ACS Chemical Biology · 2020 · 43 citations

Life Sciences, Molecular Biology, Oncology +13

Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors

Fernando Padilla, Niala Bhagirath, Shaoqing Chen et al. · Journal of Medicinal Chemistry · 2013 · 40 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Using Ovality to Predict Nonmutagenic, Orally Efficacious Pyridazine Amides as Cell Specific Spleen Tyrosine Kinase Inhibitors

Matthew C. Lucas, Niala Bhagirath, Eric Chiao et al. · Journal of Medicinal Chemistry · 2014 · 30 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16